Ropes & Gray advised EQRx in a clinical collaboration with oncology company Turning Point Therapeutics to evaluate Turning Point’s drug elzovantinib and EQRx’s drug aumolertinib for a certain type of advanced non-small cell lung cancer. The transaction was announced on October 13.
Under the terms of the agreement, Turning Point will sponsor and conduct a Phase 1b/2 clinical trial expected to begin in 2022 to evaluate the safety, tolerability and preliminary efficacy of the combination regimen.
The Ropes & Gray team was led by life sciences partner Abigail Gregor and life sciences associate Amanda White (both of Boston).
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find our more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.